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Sunlmary 
Glutamic acid decarboxylase (GAD) has been shown to be a target of autoantibodies in insulin- 
dependent diabetes (IDD). Two forms of GAD, with molecular weights of 67,000 and 65,000, 
have been cloned from separate genes. As pancreatic islet B cell destruction in IDD is an autoimmune 
process mediated by T  cells, we sought to determine if recombinant GAD67 was recognized 
by T cells in IDD subjects and particularly their first-degree relatives  with islet cell antibodies 
known to be at risk for IDD.  The central regions of human islet and brain GAD67 (amino 
acids 208-404) were cloned as fusion proteins with glutathione-S-transferase (GST). Proliferation 
of peripheral blood T  cells in the presence of recombinant GAD67 was significantly higher in 
both at-risk relatives  and recent-onset IDD subjects than in other autoimmune disease subjects 
and human histocompatibility leukocyte antigen (HLA)-matched healthy controls. Thus, 12 of 
29 (41%) at-risk relatives and 11 of 29 (38%) recent-onset IDD subjects responded to GAD67, 
compared with 1 of 7 (14%) other autoimmune disease subjects and 1 of 23 (4%) HLA-matched 
controls.  T  cell responses to GST alone or to tetanus toxoid were not different between the 
groups. These findings demonstrate that GAD67 is a target autoantigen of T cells in IDD and 
suggest the possibility that GAD-reactive T cells may delineate asymptomatic subjects at increased 
risk for IDD. 
I 
nsulin-dependent diabetes (IDD) is an autoimmune disease 
that results from T cell-mediated destruction of the pan- 
creatic islet B cells (1). Islet-reactive T  cells can be detected 
in the peripheral blood of recent-onset IDD  subjects and 
asymptomatic islet cell antibody (ICA)-positive first-degree 
relatives of persons with IDD (2). In addition to ICA, which 
react with an uncharacterized antigen in frozen sections of 
human pancreas, the majority of recent-onset IDD subjects 
and at-risk first-degree relatives have antibodies to a 64,1X10-mol 
wt  islet  antigen identified as  glutamic acid decarboxylase 
(GAD) (3).  Such subjects have recently been shown to have 
antibodies that react directly with purified native (4) or recom- 
binant  (5) GAD. 
GAD catalyzes the conversion of t-glutamate to ~/-amino 
butyric acid and is found in high concentrations in neurones 
and ~/cells (6). It exists in two forms, derived from separate 
genes encoding proteins with predicted molecular weights 
of 65,300  (GAD65)  and 66,660  (GAD67)  that  have 65% 
amino acid identity (7).  It has been proposed that GAD65 
is  the  major  islet  form  of  GAD  that  accounts  for  the 
64,000-mol wt antigen (8). Atkinson et al. (9) reported that 
T  cells from IDD subjects proliferate in response to recom- 
binant GAD65. However, it has not been shown that T cell 
responses to GAD are IDD specific, i.e., absent in other au- 
toimmune diseases. Furthermore, the key role of MHC mol- 
ecules in presenting peptides to T  cells and the association 
between specific MHC class II alleles and IDD (10) dictates 
that T cell responses of IDD subjects be compared with those 
of MHC class II-matched healthy controls to exclude the 
possibility that they are MHC rather than IDD specific. 
Materials and Methods 
Subjects.  Samples  of peripheral venous blood were obtained with 
informed consent and approval of the Human Ethics Committee 
(Royal Melbourne Hospital) from: (a) 29 first-degree relatives of 
persons with IDD defined as at-risk for IDD because of the pres- 
ence of circulating ICA at t>20  Juvenile Diabetes Foundation 0DF) 
units; (b) 29 subjects with recent-onset clinical IDD (<6 wk after 
diagnosis); (c) seven subjects with other autoimmune diseases (four 
Graves' disease, one sderoderma, two Sj6gren's syndrome); and (d) 
23 healthy control subjects HLA matched for HLA-DR and DQ 
with subjects in groups a and b (Table 1). 
HLA  Typing.  HLA typing was performed serologically on all 
subjects by the standard microlymphocytotoxic technique for all 
recognized HLA class I and II alleles. The class II typings of at-risk 
and recent-onset IDD subjects were confirmed by sequence specific 
oligotyping following the 11th International Histocompatibility 
Workshop protocol. 
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Subjects  Age  Sex  HLA DR;DQ  Basal 
T  cell proliferation 
GST  HIG  HBG  Tetanus  HIG* 
yr  clam 
ICA + first-degree  relatives 
1  37  F  3,12;  2,7  4,044  16,811  22,168 
2  11  M  2,4;  1,9  2,497  2,980  16,632 
3  18  F  3,4;  2,8  5,923  6,225  15,325 
4  6  M  3,4;  2,8  4,703  4,685  55,491 
5  48  M  3,4;  2,8  2,417  2,638  9,660 
6  17  F  3,3;  2,2  3,501  9,360  14,891 
7  49  M  3,4;  2,8  5,510  4,314  30,766 
8  49  F  3,4;  2,7  6,514  10,079  15,364 
9  11  M  4,13;  1,7  5,044  5,376  26,875 
10  33  M  4,13;  1,8  2,234  6,379  7,769 
11  30  M  2,3;  1,2  3,258  18,271  35,889 
12  13  M  1,3;  1,2  17,233  30,086  37,459 
13  40  F  2,9;  1,9  2,539  85,376  118,842 
14  44  F  3,3;  2,2  17,334  25,181  28,211 
15  49  M  4,8;  4,7  5,250  5,059  7,044 
16  10  F  4,4;  7,8  2,486  3,040  13,444 
17  11  M  3,3;  2,2  5,645  4,804  35,112 
18  16  M  3,4;  2,8  380  2,210  6,311 
19  11  F  4,4;  8,8  1,527  7,474  19,602 
20  19  M  -  877  756  2,363 
21  5  M  -  13,533  13,222  17,595 
22  6  M  1,4;  1,8  75  710  1,616 
23  19  M  3,4;  2,8  6,517  9,307  10,787 
24  43  F  3,4;  2,8  11,854  51,287  39,010 
25  21  F  4,11;  6,7  5,639  8,193  29,855 
26  14  F  3,4;  2,8  20,677  21,763  73,153 
27  14  M  3,3;  2,2  635  1,561  1,316 
29  39  M  3,7;  2,2  1,793  1,450  2,065 
29  45  F  3,3;  2,2  9,213  18,346  31,828 
Recent-onset  IDD 
1  35  F  3,4;  2,8  4,260  6,327  43,265 
2  12  F  3,4;  2,7  23,298  28,766  114,244 
3  -  F  -  16,609  8,907  16,533 
4  12  M  3,3;  2,2  1,139  1,419  7,424 
5  35  M  4,13;  6,7  1,243  13,424  19,108 
6  16  M  1,8;  1,8  76,450  62,764  106,254 
7  11  M  -  2,314  3,489  4,750 
8  10  F  4,6;  1,8  38,460  46,376  85,127 
9  30  M  4,4;  8,8  4,786  543  6,222 
10  28  M  4,4;  8,8  2,731  5,189  27,583 
11  20  M  4,11;  7,7  23,032  28,279  14,116 
SI 
16,406  10,651  1.3 
21,391  28,275  5.5 
42,746  22,516  1.5 
53,118  34,627  11 
6,447  17,688  2.9 
6,800  60,838  1.6 
25,934  24,554  4.8 
6,512  24,254  0.81 
75,874  21,871  4.3 
5,777  9,939  0.62 
29,719  45,356  5.4 
31,931  71,331  0.43 
77,310  86,180  13 
35,744  25,181  0.17 
6,848  17,366  0.38 
-  18,401  4.2 
38,853  20,438  5.4 
6,717  21,449  11 
-  33,719  7.9 
725  30,924  1.8 
50,553  72,337  0.32 
2,105  2,399  12 
6,064  38,730  0.22 
34,438  18,231  -  1.0 
30,671  68,950  3.8 
20,273  45,305  2.5 
1,744  8,269  - 0.38 
2,562  1,844  0.34 
14,774  6,600  1.5 
62,995  54,057  8.7 
57,288  132,359  3.7 
18,728  14,447  0.46 
8,009  27,497  5.3 
17,775  54,493  4.5 
74,274  32,583  0.57 
3,951  21,235  0.54 
116,728  167,211  1.0 
-  72,892  1.2 
8,466  28,730  8.2 
28,591  18,725  - 0.61 
continued 
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Subjects  Age  Sex 
T  cell proliferation 
HLA DR:DQ  Basal  GST  HIG  HBG  Tetanus  HIG* 
12  26  F  3,4;  2,8  14,701  24,347 
13  13  F  -  24,227  59,473 
14  11  M  -  10,020  10,990 
15  17  M  1,4;  1,8  9,891  10,418 
16  17  M  1,4;  1,8  3,145  12,562 
17  19  M  3,4;  2,8  8,872  4,903 
18  45  F  -  4,828  6,740 
19  20  F  4,4;  7,8  1,842  2,324 
20  26  M  3,4;  2,8  8,795  8,442 
21  22  M  3,4;  2,8  4,363  6,160 
22  35  F  3,4;  2,8  4,306  20,991 
23  24  F  4,8;  4,8  41,386  39,098 
25  35  F  1,3;  1,2  61,432  84,724 
26  12  M  3,4;  2,8  6,530  10,345 
27  15  M  3,4;  2,8  38,414  76,673 
28  17  M  3,4;  2,8  55,326  44,410 
29  39  M  3,3;  2,2  4,299  44,788 
Autoimmune disease controls  (1-4, 
1  38  F 
2  30  F 
3  64  F 
4  29  F 
5  40  F 
6  48  F 
7  23  F 
Healthy  controls 
1  37  M 
2  24  M 
3  34  M 
4  30  F 
5  30  F 
6  27  F 
7  20  M 
8  30  F 
9  21  M 
10  28  F 
11  38  M 
12  38  M 
13  11  M 
14  7  M 
15  30  F 
16  32  M 
17  37  F 
Graves' disease; 5,  Scleroderma; 6 and 
9,11;  7,9  8,026  10,114 
3,4;  2,7  4,910  4,080 
3,11;  2,7  11,552  7,899 
-  9,598  17,311 
-  680  948 
2,10;  1-  1,930  1,902 
2,3;  1,2  9,281  12,001 
2,13;  1,6  16,306  15,587 
3,BR;  1,2  14,840  28,631 
1,4; 1,7  1,851  4,298 
3,4;  2,8  4,379  5,278 
3,3;  2,2  4,992  4,702 
3,4;  2,8  3,063  6,179 
4,4;  7,7  30,402  35,130 
4,7;  2,7  3,372  16,388 
4,11;  7-  9,335  18,197 
3,4;  2,8  2,543  8,967 
2,4;  1,7  9,105  10,579 
4,4;  8,8  13,433  2,974 
13,11;  1,7  16,246  36,983 
13,11; 1,7  8,750  26,835 
4,4;  3,3  17,937  17,210 
4,13;  1,8  42,955  65,488 
1,2; 1,1  3,348  2,779 
30,905  -  34,541  0.45 
56,536  43,729  43,347  - O. 12 
27,201  32,581  13,260  1.6 
19,463  29,211  13,902  0.91 
38,110  20,092  93,221  8.1 
2,383  6,247  11,799  - 0.28 
24,684  9,073  8,228  3.7 
17,194  21,049  24,523  8.1 
53,244  -  53,039  5.1 
47,786  30,560  80,174  9.5 
34,864  -  96,886  3.2 
44,012  -  39,533  0.12 
116,462  -  88,052  0.52 
23,040  -  38,011  1.9 
82,711  111,631  114,511  0.16 
37,809  54,565  -  - 0.12 
41,751  35,944  15,752  -  0.70 
7,  Sj6gren's syndrome) 
53,926  69,244 
4,941 
14,744  9,333 
14,023  39,382 
1,015  972 
2,452  2,378 
21,133  19,849 
43,900 
7,365 
43,952 
32,088 
1,119 
1,436 
132,223 
5.5 
0.17 
0.59 
- 0.34 
0.10 
0.28 
0.98 
20,458  20,651  122,493  0.29 
39,208  33,215  18,871  O. 71 
2,256  2,550  10,542  -  1.1 
4,639  -  14,072  - 0.15 
4,278  -  11,387  - 0.085 
9,722  5,792  70,122  1,2 
66,277  -  59,000  1.0 
25,106  21,379  21,211  2.6 
28,662  39,243  44,958  1.1 
18,054  15,047  76,630  3.6 
30,983  32,205  47,088  2.2 
2,932  -  4,868  - 0.012 
29,438  47,240  81,429  - 0.46 
35,926  32,426  92,180  1.0 
27,982  21,329  90,812  0.60 
44,390  81,628  87,938  - 0.49 
4,233  1,863  11,454  0.43 
continued 
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Subjects  Age  Sex  HLA DR:DQ  Basal  GST 
T  cell proliferation 
HIG  HBG  Tetanus  HIG* 
18  37  M  4,12;  7,8  9,842  14,180 
19  39  M  4,11;  7,7  1,948  3,415 
20  51  F  2,3;  1,2  1,770  2,433 
21  30  M  3,3;  2,2  21,979  33,832 
22  48  F  3,3;  2,2  1,859  3,646 
23  40  M  3,4;  2,8  12,619  23,868 
30,373  19,014  44,798  1.6 
6,689  5,530  23,297  1.7 
2,655  2,952  2,154  0.12 
48,668  36,426  60,850  0.67 
6,505  6,095  21,249  1.5 
14,032  13,874  58,826  -  0.78 
* The stimulation index (SI) for HIG was corrected by subtracting the index for GST alone. 
Recombinant  Antigens.  Cloning and sequencing of the central 
region (amino acids 208-404) of human brain GAD67 (HBG 584 
amino acids) has been previously described (11). The equivalent re- 
gion of human islet GAD67 (HIG) was obtained by reverse tran- 
scription of total islet  RNA and amplified  using the PCK (11). 
The predicted amino acid sequence of HIG was identical to HBG 
except for a leucine for phenylalanine substitution at position 248. 
Both partial GAD67 cDNA fragments were cloned into SmaI- and 
EcoRI-cleaved DNA of the pGEX-3 expression vector downstream 
from glutathionine-S-transferase  (GST). HIG and HBG fusion pro- 
teins and the control GST protein were expressed in Escherichia coli 
and ai~ity purified on glutathione-agarose beads (11). Proteins were 
eluted from the beads with 10 mM reduced glutathione, 50 mM 
Tris pH 8.0, dialyzed against human tonicity PBS, filter sterilized, 
and stored at  -70~  Preparations were free of endotoxin as de- 
termined in the limulus lysate assay and were homogeneous by SDS- 
PAGE (Fig.  1). 
Antibody Assays.  ICA were assayed  by indirect immunofluores- 
cence on cryostat sections  of human pancreas  (blood group O), 
according to the protocol of the Second International Workshop 
on the Standardization of Islet Cell Antibodies. 
T  Cell Proliferation Assays.  PBMC were isolated  from hepari- 
nized blood by Ficoll-Hypaque density centrifugation, washed twice 
in  RPMI  1640,  and diluted to 2￿  106/ml  in  RPMI  1640 con- 
taining 5% autologous serum and 10 -s M 2-ME. Cells were dis- 
tributed in 200-/zl aliquots into wells of 96-well flat-bottomed Linbro 
trays, and 10/~1 of antigen/well was added to quadruplicate wells. 
No antigen was added to cells in sets of quadruplicate wells at the 
beginning,  middle, and end of the tray. Recombinant proteins (HIG, 
HBG, GST control) were added at 200, 2, and 0.2 #g to provide 
final concentrations of 10, 1, and 0.1 #g/ml. Tetanus toxoid (Com- 
monwealth Serum Laboratories,  Melbourne,  Australia)  without 
thiomersal was used as a positive control antigen at final concen- 
trations of 1.8, 0.18, and 0.018 Lyons floculating units (LFU)/ml. 
After  7  d  of  incubation  in  5%  CO2/air  at  37~  1.0  /zCi 
[~H]thymidine was  added  to  each  well,  the  cultures  harvested 
semi-automatically  7 h later, and thymidine incorporation measured 
by liquid scintillation counting. Proliferation was expressed as the 
stimulation index (SI), the median counts per minute (cpm) of the 
maximum response to antigen divided by the median cpm in the 
absence of antigen. Sis for HIG and HBG were corrected by sub- 
traction of responses  to GST alone.  The threshold for a positive 
response was set at an SI of 3.0. This excluded  all but one of the 
healthy controls. Differences between groups were analyzed using 
Wilcoxon's rank sum test. The correlation coefficient between paired 
responses  was  calculated by t test. 
Sequence Screening.  The GAD amino acid sequence was com- 
pared against all nucleic acid databases using the National Center 
for  Biotechnology  Information/National  Library  of Medicine 
T-BLAST program. 
Results and Discussion 
PBMC from 12 of 29 (41%) ICA-positive first-degree rela- 
tives responded to HIG compared with 11 of 29 (38%) recent- 
onset IDD  subjects,  1 of 7  (14%)  subjects with  other au- 
toimmune diseases, and I of 23 (4%) HLA-matched, healthy 
controls  (Fig.  2).  Proliferative  responses  to  HIG  were 
significantly greater than those of healthy controls in the first- 
degree relatives (p <0.01) but just failed to reach significance 
in recent-onset IDD subjects; responses to HBG in first-degree 
relatives and recent-onset IDD subjects were both significantly 
greater than in healthy controls (p <0.003 andp <0.05, respec- 
tively). Autoimmune controls were not significantly different 
from healthy controls in response to either antigen.  As ex- 
pected, given their near identity,  proliferative responses  to 
HBG were overall no different from those to HIG. The tight 
Figure 1.  SDS-PAGE  analysis 
of glutathione  af~nity purified 
recombinant  GST fusion  proteins. 
Proteins were subjected to dec- 
trophoresis  in a 12.5% acrylamide 
gel and stained with coomassie 
blue. Lane I, molecular size mar- 
kers; lane 2,  GST-human islet 
GAD67;  lane  3,  GST-human 
brain GAD67; lane 4, GST. 
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Figure 2.  Proliferation  of  peripheral  blood  T cells  in response  to recom- 
binant human islet GAD67 (amino acids 208-404). 
correlation (r  =  0.90) between the SI values for HIG and 
HBG for all  subjects provided an internal measure of the 
specificity and precision of the results.  In contrast to HIG 
or HBG, proliferative responses to tetanus toxoid were not 
significantly different between groups. 
These results demonstrate that peripheral blood T cells that 
proliferate in response to the central region of human GAD67 
can be detected not only in some recent-onset IDD subjects 
but also in an equivalent proportion of asymptomatic, ICA- 
positive first-degree relatives of IDD subjects. GAD-reactive 
T  cells were not detected in most subjects with other au- 
toimmune diseases,  indicating that  GAD67  responses  are 
specific for IDD. The association of IDD with specific MHC 
class II alleles (e.g., HLA-DR3,4; DQ 2,8) predicts that APC 
bearing these alleles will preferentially process and present 
diabetogenic peptides to T  cells. If all individuals possessed 
potentially autoreactive T cells and if GAD peptides in sus- 
ceptible MHC molecules trigger GAD-specific T cell prolifer- 
ation, then healthy control subjects with the same MHC al- 
leles might also be expected to respond. However, only one 
of nine (11%) healthy controls with HLA-DR3 had significant 
T cell responses, compared with 5 of 18 (28%) of ICA-positive 
first-degree relatives and 6 of 13 (46%) recent-onset IDD sub- 
jects. 1 of 14 (7%) healthy controls with DR4 had significant 
T cell responses compared with 9 of 17 (53%) ICA-positive 
relatives and 9 of 19 (47%) IDD subjects. One of seven (14%) 
healthy controls with DQw8 had significant responses, com- 
pared with 6 of 12 (50%) ICA-positive relatives and 7 of 17 
(41%)  IDD subjects.  For the full-susceptibility phenotype 
DR3,4;DQ2,8,  one  of four  (25%)  healthy controls  had 
significant responses, in comparison with three of eight (38%) 
ICA-positive relatives and four of nine (44%) IDD subjects. 
Thus, the higher responses in ICAopositive relatives and IDD 
subjects are disease rather than MHC specific. These findings 
may be explained by a higher frequency of GAD-specific T 
cells in a subset of subjects with/3 cell autoimmunity. T cell 
responses were specific not only for IDD but also for GAD 
because the responses to GST and tetanus toxoid were not 
significantly different between the subject groups. 
T cell responses to GAD67 in ICA-positive relatives mirror 
those to whole fetal pig proislets (2), in accord with the evi- 
dence that T  cell-mediated destruction of/3 cells precedes 
the onset of symptomatic disease. Nevertheless, less than half 
of our ICA-positive first-degree relatives exhibited T cell re- 
sponses to GAD. Although ICA are predictive for IDD, not 
all ICA-positive first-degree relatives and even fewer ICA- 
positive individuals without a relative with IDD will develop 
IDD (12). In addition, GAD is clearly not the only antigen 
responsible for T  cell reactivity to islets  in IDD (13).  The 
combination of two or more tests of islet immunity should 
improve the prediction of disease. The first test, if highly sen- 
sitive like ICA, would exclude individuals not at risk and 
effectively increase the number with preclinical IDD in the 
remainder, who could then be screened with a second, prefer- 
ably more specific test. As/3 cell destruction is a T cell-medi- 
ated process, it would be logical if the second test measured 
T cell reactivity to islet antigens. Accordingly, it is tempting 
to speculate that ICA-positive individuals who also have T 
cell reactivity to GAD represent a higher risk subgroup. Lon- 
gitudinal studies will establish whether this hypothesis is cor- 
rect. The group of ICA-positive relatives who were T  cell 
responders contained relatively more males (M/F, 8:4) than 
the nonresponders (M/F, 9:8) and were younger (mean age, 
18.5 vs 29.8 yr, respectively). The only ICA-positive rela- 
tives to develop IDD during the 18-mo course of this study 
were two young males (17 and 18 in Table 1) within the T 
cell responder group. 
An increased risk  of IDD  in  relatives who  are T  cell 
responders  would  predict  a  higher  frequency  of T  cell 
responders in recent-onset IDD subjects,  but this was not 
the case in our cross-sectional study. It is possible that the 
near-total loss of/3 cells at the time of symptomatic disease 
removes the antigenic drive to maintain T cell activation. T 
cell responses to whole fetal pig proislets were less frequent 
and lower in recent-onset IDD subjects than in ICA-positive 
relatives (2). Alternatively, recent-onset IDD subjects may 
respond to a greater number of epitopes in GAD than is present 
in the 208-404 amino acid region tested here. Atkinson et 
al. (9) found T cell proliferative responses to full-length recom- 
binant GAD65 in five of eight (63%) ICA-positive relatives 
and 12 of 18 (67%) recent-onset IDD subjects.  Comparison 
of GAD65 with the central 208-404  amino acid region of 
GAD67 used by us reveals 22 (11%) nonconservative substi- 
tutions and 24 (12%) conservative substitutions. Therefore, 
this central region of GAD could contain T cell epitopes unique 
to each of the two forms of GAD. The frequency of responses 
to GAD65 was apparently higher than to GAD67 but the 
number of subjects, especially ICA-positive relatives, was con- 
siderably less than in the present study. Although the differ- 
ences are consistent with the existence of T cell epitopes in 
the NH2- and COOH-terminal thirds of the protein, or re- 
activity with unique epitopes in the central region of GAD65, 
our epitope mapping studies using overlapping 13-mer GAD 
peptides indicates that the central region of GAD contains 
the dominant epitope (M. C. Honeyman and L. C. Harrison, 
unpublished results). 
The GAD67 central region contains a sequence (amino acids 
258-281) with homology to the P2-C protein of Coxsackie 
virus B4 (14). Eight residues are identical to the Coxsackie 
539  Honeyman  et al.  Brief  Definitive Report sequence; nine residues are identical in the equivalent sequence 
of GAD65.  When we screened  this sequence  of GAD67 
against all nucleic acid data bases, several other homologous 
viral sequences were revealed in Kunjin virus, Japanese en- 
cephalitis virus, Western Nile virus, and Murray Valley en- 
cephalitis virus. This spectrum of viruses with sequence ho- 
mology to GAD  provides  a  plausible  basis  for molecular 
mimicry at the level of the T  cell epitope. 
The identification of GAD as a T cell autoantigen in IDD 
raises a number of critical questions. How early in the course 
of preclinical IDD are GAD-reactive T cells detected and do 
they predict clinical IDD better than antibodies to islet an- 
tigens? Definition of the primary T cell epitope of GAD might 
provide insight into a possible viral etiology of IDD and should 
refine the diagnosis of preclinical IDD and facilitate therapeutic 
strategies such as tolerance induction. 
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